HRMY Harmony Biosciences
- 39.240
- -0.760-1.90%
- 39.240
- 0.0000.00%
Harmony Biosciences News
A Quick Look at Today's Ratings for Harmony Biosciences(HRMY.US), With a Forecast Between $44 to $56
Harmony Biosciences Analyst Ratings
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Harmony Biosciences Price Target Maintained With a $52.00/Share by Needham
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Harmony Biosciences Analyst Ratings
UBS Initiates Coverage On Harmony Biosciences With Buy Rating, Announces Price Target of $56
UBS Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $56
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY) and McKesson (MCK)
Harmony Biosciences Holdings (HRMY) Receives a Buy From Oppenheimer
Harmony Biosciences Price Target Maintained With a $52.00/Share by Needham
Harmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue Guidance
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Announces Target Price $28
Harmony Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Elevation Oncology (ELEV) and Harmony Biosciences Holdings (HRMY)
Buy Rating Affirmed for Harmony Biosciences on Strong Earnings and Promising Drug Formulation Prospects
Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Piper Sandler Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)
Analysis
Price Target
No Data
No Data